Current and historical daily PE Ratio for Viatris Inc (
) from 1990 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Viatris stock (VTRS) PE ratio as of Apr 27 2024 is 289.25.
More Details
Viatris Inc (VTRS) PE Ratio (TTM) Chart
Viatris Inc (VTRS) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1217
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Viatris PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 289.3 | 2024-02-23 | 338.3 |
| 2024-04-26 | 289.3 | 2024-02-22 | 334.0 |
| 2024-04-25 | 286.8 | 2024-02-21 | 331.5 |
| 2024-04-24 | 288.8 | 2024-02-20 | 331.0 |
| 2024-04-23 | 284.0 | 2024-02-16 | 326.5 |
| 2024-04-22 | 281.3 | 2024-02-15 | 320.5 |
| 2024-04-19 | 281.3 | 2024-02-14 | 301.8 |
| 2024-04-18 | 278.0 | 2024-02-13 | 299.3 |
| 2024-04-17 | 277.5 | 2024-02-12 | 298.8 |
| 2024-04-16 | 278.0 | 2024-02-09 | 292.0 |
| 2024-04-15 | 283.0 | 2024-02-08 | 289.0 |
| 2024-04-12 | 283.3 | 2024-02-07 | 293.5 |
| 2024-04-11 | 289.3 | 2024-02-06 | 297.3 |
| 2024-04-10 | 292.8 | 2024-02-05 | 289.5 |
| 2024-04-09 | 295.5 | 2024-02-02 | 296.3 |
| 2024-04-08 | 293.8 | 2024-02-01 | 296.8 |
| 2024-04-05 | 295.0 | 2024-01-31 | 294.3 |
| 2024-04-04 | 294.0 | 2024-01-30 | 295.3 |
| 2024-04-03 | 300.5 | 2024-01-29 | 297.0 |
| 2024-04-02 | 298.5 | 2024-01-26 | 298.3 |
| 2024-04-01 | 298.5 | 2024-01-25 | 293.5 |
| 2024-03-28 | 298.5 | 2024-01-24 | 293.0 |
| 2024-03-27 | 295.8 | 2024-01-23 | 294.3 |
| 2024-03-26 | 290.0 | 2024-01-22 | 291.0 |
| 2024-03-25 | 295.8 | 2024-01-19 | 285.0 |
| 2024-03-22 | 296.0 | 2024-01-18 | 281.8 |
| 2024-03-21 | 300.3 | 2024-01-17 | 286.5 |
| 2024-03-20 | 297.0 | 2024-01-16 | 293.8 |
| 2024-03-19 | 296.8 | 2024-01-12 | 292.0 |
| 2024-03-18 | 294.0 | 2024-01-11 | 301.8 |
| 2024-03-15 | 298.5 | 2024-01-10 | 302.5 |
| 2024-03-14 | 295.5 | 2024-01-09 | 290.0 |
| 2024-03-13 | 301.3 | 2024-01-08 | 292.8 |
| 2024-03-12 | 301.5 | 2024-01-05 | 299.5 |
| 2024-03-11 | 299.3 | 2024-01-04 | 288.8 |
| 2024-03-08 | 306.5 | 2024-01-03 | 284.3 |
| 2024-03-07 | 308.3 | 2024-01-02 | 284.8 |
| 2024-03-06 | 305.0 | 2023-12-29 | 270.8 |
| 2024-03-05 | 307.0 | 2023-12-28 | 271.3 |
| 2024-03-04 | 309.0 | 2023-12-27 | 7.1 |
| 2024-03-01 | 314.8 | 2023-12-26 | 7.1 |
| 2024-02-29 | 309.3 | 2023-12-22 | 7.0 |
| 2024-02-28 | 307.3 | 2023-12-21 | 7.0 |
| 2024-02-27 | 330.8 | 2023-12-20 | 6.9 |
| 2024-02-26 | 335.8 | 2023-12-19 | 6.9 |
Viatris Inc (VTRS) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Viatris Inc
NAICS : 325411
SIC : 2833
ISIN : US92556V1061
Compare
Compare
Traded in other countries / regions
VTRS.USA0A5V.UKVIA.GermanyMYL.MexicoMYL.Austria1VTRS.Italy IPO Date
1986-04-14Description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers